» Articles » PMID: 34490029

Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence

Overview
Journal Front Genet
Date 2021 Sep 7
PMID 34490029
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prostate cancer (PCa) is an immune-responsive disease. The current study sought to explore a robust immune-related prognostic gene signature for PCa.

Methods: Data were retrieved from the tumor Genome Atlas (TCGA) database and GSE46602 database for performing the least absolute shrinkage and selection operator (LASSO) cox regression model analysis. Immune related genes (IRGs) data were retrieved from ImmPort database.

Results: The weighted gene co-expression network analysis (WGCNA) showed that nine functional modules are correlated with the biochemical recurrence of PCa, including 259 IRGs. Univariate regression analysis and survival analysis identified 35 IRGs correlated with the prognosis of PCa. LASSO Cox regression model analysis was used to construct a risk prognosis model comprising 18 IRGs. Multivariate regression analysis showed that risk score was an independent predictor of the prognosis of PCa. A nomogram comprising a combination of this model and other clinical features showed good prediction accuracy in predicting the prognosis of PCa. Further analysis showed that different risk groups harbored different gene mutations, differential transcriptome expression and different immune infiltration levels. Patients in the high-risk group exhibited more gene mutations compared with those in the low-risk group. Patients in the high-risk groups showed high-frequency mutations in TP53. Immune infiltration analysis showed that M2 macrophages were significantly enriched in the high-risk group implying that it affected prognosis of PCa patients. In addition, immunostimulatory genes were differentially expressed in the high-risk group compared with the low-risk group. BIRC5, as an immune-related gene in the prediction model, was up-regulated in 87.5% of prostate cancer tissues. Knockdown of BIRC5 can inhibit cell proliferation and migration.

Conclusion: In summary, a risk prognosis model based on IGRs was developed. A nomogram comprising a combination of this model and other clinical features showed good accuracy in predicting the prognosis of PCa. This model provides a basis for personalized treatment of PCa and can help clinicians in making effective treatment decisions.

Citing Articles

Exploring BIRC family genes as prognostic biomarkers and therapeutic targets in prostate cancer.

Yu X, Liu Y, Mo Z, Luo R, Chen W Discov Oncol. 2025; 16(1):240.

PMID: 40009266 PMC: 11865399. DOI: 10.1007/s12672-025-02002-7.


TP53 Deficiency in the Natural History of Prostate Cancer.

Ofner H, Kramer G, Shariat S, Hassler M Cancers (Basel). 2025; 17(4).

PMID: 40002239 PMC: 11853097. DOI: 10.3390/cancers17040645.


Identification of fatty acid anabolism patterns to predict prognosis and immunotherapy response in gastric cancer.

Sun W, Xia Y, Jin F, Cao J, Wu G, Li K Discov Oncol. 2025; 16(1):6.

PMID: 39755916 PMC: 11700077. DOI: 10.1007/s12672-025-01745-7.


BIRC5 knockdown ameliorates hepatocellular carcinoma progression via regulating PPARγ pathway and cuproptosis.

Mai Y, Ji Z, Tan Y, Feng L, Qin J Discov Oncol. 2024; 15(1):706.

PMID: 39585552 PMC: 11589110. DOI: 10.1007/s12672-024-01592-y.


AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy.

He A, Huang Z, Feng Q, Zhang S, Li F, Li D J Transl Med. 2024; 22(1):809.

PMID: 39217342 PMC: 11366154. DOI: 10.1186/s12967-024-05576-y.


References
1.
Davidsson S, Andren O, Ohlson A, Carlsson J, Andersson S, Giunchi F . FOXP3 regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. Prostate. 2017; 78(1):40-47. PMC: 5725695. DOI: 10.1002/pros.23442. View

2.
Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

3.
Cho S, Pak K, Jeong D, Han M, Oh S, Kim Y . The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma. J Cell Biochem. 2018; 120(3):4140-4146. DOI: 10.1002/jcb.27699. View

4.
Maia M, Hansen A . A comprehensive review of immunotherapies in prostate cancer. Crit Rev Oncol Hematol. 2017; 113:292-303. DOI: 10.1016/j.critrevonc.2017.02.026. View

5.
Farkona S, Diamandis E, Blasutig I . Cancer immunotherapy: the beginning of the end of cancer?. BMC Med. 2016; 14:73. PMC: 4858828. DOI: 10.1186/s12916-016-0623-5. View